Dosing: Daily subcutaneous injection Maximum dose: 3.0 mg/day Average weight loss (SCALE trial): 8% over 56 weeks List price: ~$1,349/mo FDA-approved for: Adults and adolescents 12+ with BMI 30 (or 27 with comorbidities) Zepbound (Tirzepatide) The 2023 Newcomer Zepbound, FDA-approved in November 2023, contains tirzepatide a dual GIP/GLP-1 receptor agonist
By boosting insulin sensitivity, tesofensine might help keep blood sugar levels normal
Dorsal and palmar branches of the anterior interosseous artery supply the more radial part of the complex
WEIGHT-LOSS DRUGS TO GET SURPRISING ENDORSEMENT FROM GLOBAL HEALTH GIANT Dr
Zheng M, Xie C, Ye D, et al
"Body composition outcomes in obesity pharmacotherapy: clinical significance and measurement challenges." Reviews in Endocrine and Metabolic Disorders